Urothelial Carcinoma Diagnostics
Advertisement
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
How can clinical tools like circulating tumor DNA inform bladder cancer treatment adjustments and transitions?
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Djaladat discusses how the presence of specific biomarkers, such as CK|V oncosomes and D|CK|V cells, correlate with RFS.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
Liquid biopsy can benefit patients with UTUC by detecting rare events at higher incidences compared to tissue-based samples.
Researchers investigated the ability of variant histology to predict oncological outcomes.
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.